| Literature DB >> 34676042 |
Hodaya Gutman1, Andrii Bazylevich1, Chandrashekhar Prasad1, Ortal Dorfman1, Arkadi Hesin2, Vered Marks1, Leonid Patsenker1, Gary Gellerman1.
Abstract
We developed a highly potent anticancer agent, dolastatinol, which is a methylene hydroxyl derivative of dolastatin 10. Dolastatinol is a synthetic analog of dolastatin 10, synthesized by a solid-phase peptide Fmoc chemistry protocol on 2-chlorotrityl chloride resin utilizing a pH-triggering self-immolative monosuccinate linker. The introduction of the C-terminus hydroxyl methylene functionality preserves the anticancer properties of the parent dolastatin 10, including strong suppression of the cell proliferation, migration, high cytotoxicity. Our research establishes a new facile route toward the further development of C-terminus-modified dolastatin-10-based microtubule inhibitors for anticancer treatment.Entities:
Year: 2021 PMID: 34676042 PMCID: PMC8521654 DOI: 10.1021/acsmedchemlett.1c00432
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632